Source For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Bringing together Arterys’ AI applications and Ambra’s platform opens the door for improved research and development, as well as patient care, said Ambra officials. This partnership brings together Arterys’ seven AI solutions that have been cleared by the U.S. Food & Drug Administration, including Cardio AI, Lung AI, and Neuro AI, with Ambra’s interoperable, customizable cloud platform that consolidates multiple imaging systems that allows for secure access to imaging data anywhere, anytime.
“Arterys has demonstrated that AI has rapidly moved from theory to practice. But, in order for AI programs to be effective, imaging data can’t operate in silos or disparate systems,” said Andrew Duckworth, Ambra Health vice president of business development. “By partnering with Arterys, we’re making it seamless for physicians to layer on innovative AI solutions to their existing Ambra cloud technology.” Related Content: Columns from Morris Panner, Ambra Health CEO
The News Highlights
- Ambra Health-Arterys partnership accelerates AI
- Check the latest Health news updates and information about health.